Discussion
dyspnea, SARS-CoV-2 infection, hyper-inflammatory, infection, hypoxemia, systemic disorder
SARS-COV-2 INFECTION, GROUP B, SILENT HYPOXIA, INFLAMMATORY RESPONSES, DISEASE, HYPOXIC, INFECTION, INFLAMMATORY RESPONSE
The majority of SARS-CoV-2 infections had either no or mild symptoms. But there is also a significant proportion of infected individuals who suffer from a severe hyper-inflammatory and hypoxic response that entails the development of a potent and effective treatment for COVID-19. The result of this clinical trial demonstrated that the early-onset of oral treatment with In our study, the average viral clearance observed was 13.92 days (95% CI 12.85–14.99) in Group A, 13.44 days (95% CI 12.14–14.74) in Group B and 11.86 days (95% CI 10.62–13.11) days in Group C. Furthermore, we also observed the median time taken to normal body temperature was 4 days in Group A and C, and 3 days in Group C. On the 7th day, 88% of patients in Group A and 90% of patients in Groups B and C had achieved normal temperature below 98.6 °F after treatment. This observation is comparable with another study in which avifavir, an RNA polymerase inhibitor, the treated group had a median time of two days to normalize body temperature and 4 days in the standard of care group [Daily monitoring of oxygen saturation (SpOIn addition to the clinical symptoms and viral clearance, we wanted to test the effect of SARS-CoV-2 is a systemic disorder that involved multiorgan effects to some extent. To estimate the overall safety of these drugs, we evaluated systemic health parameters such as CBC, ESR, PT, PT/INR, liver function, kidney function, and lipid profile. In our patient’s group, most parameters were within normal limits and were largely unaffected or altered within normal limits in all three groups. Almost half of SARS-CoV-2 infected individuals showed some impairment in their liver function and elevated liver enzymes [The overall decline in the systemic health parameters has been observed and reported in literature during the course of the disease [It is reported that without any indications of respiratory discomfort or dyspnea, patients with COVID-19 are frequently shown to have life-threatening hypoxemia which is termed as Silent hypoxia. The viral ORF3a protein is shown to increase the production of HIF-1α during SARS-CoV-2 infection, which in turn promotes the inflammatory responses and subsequently the infection. Since HIF-1α is a critical promoter of both SARS-CoV-2 infection and inflammatory response, it is suggested as a viable therapeutic target for COVID-19 and virus-induced inflammatory infection [Although this analysis provided in-depth understanding of the clinical effects of tested formulation in COVID-19 patients, it has two limitations. One, due to the highly contagious nature of the disease, the patient's willingness to comply with blood sample collections was adversely affected. As a result, this left us with less than half of the patients from whom three-timepoint sample workups. Second, the study did not include a placebo control group. In the context of the COVID-19 pandemic, the absence of established therapeutic interventions necessitated the implementation of symptomatic management as the prevailing standard of care. The Government of India, Ministry of AYUSH, subsequently issued guidelines for the management of COVID-19, incorporating Ayurvedic medicines, with This study demonstrated the effects of 